Affected investors can register claims against the companies on the Sina Investor Rights Protection Platform.

On November 17, 2025, lawyer Xu Feng from Shanghai Jiucheng Law Firm submitted another batch of investor claims against Nanjing Aolian Ae&Ea (300585) for false statements to the court.

Some cases represented by Xu Feng have already secured compensation, while the legal team continues to file additional claims and accepts further investor mandates.

On April 7, 2024, Nanjing Aolian Ae&Ea announced receiving the "Administrative Penalty Decision" from the China Securities Regulatory Commission (CSRC). The investigation found that the company had made misleading statements regarding Xu Mingjun’s performance in the perovskite sector, including exaggerated claims about his industry achievements and core competitiveness.

Between February 21 and 22, 2023, following a clarification statement from Huaneng Clean Energy Research Institute, Nanjing Aolian Ae&Ea’s stock price fell by 29.92%, significantly underperforming the ChiNext Index (-1.16%) and the Wind Perovskite Battery Index (-2.19%).

Xu Feng advises that investors who bought Nanjing Aolian Ae&Ea shares between December 12, 2022, and February 21, 2023 (noon), and sold or held them afterward may still file claims, with the statute of limitations expiring in three months.

Separately, on November 17, Xu Feng also submitted investor claims against Hainan Poly Pharm (300630) to the court. Some cases have received assessment reports from the Haikou Intermediate People’s Court, with hearings underway.

On March 21, 2025, Hainan Poly Pharm disclosed receiving the CSRC’s penalty decision, which revealed fabricated sales and inflated profits from 2021 to 2022. The company overstated 2021 revenue by 28.94% (CNY 436.6M) and 2022 revenue by 25.28% (CNY 456.6M), with corresponding inflated profits.

Investors who purchased Hainan Poly Pharm shares between April 26, 2022, and April 17, 2024, and sold or held them afterward may still pursue claims.